Aspira Women's Health Inc. Partners with Dorsata to Launch Adnexal Mass Clinical Tool, Expanding Access to 1.5 Million Patients Across 300+ Practices

Reuters06-17

<a href="https://laohu8.com/S/AWH">Aspira Women's Health Inc.</a> Partners with Dorsata to Launch Adnexal Mass Clinical Tool, Expanding Access to 1.5 Million Patients Across 300+ Practices

Aspira Women's Health Inc. has announced a new collaboration with Dorsata to launch a clinical decision support module for adnexal masses. This partnership aims to modernize women's healthcare by integrating tech-enabled clinical tools to facilitate early detection and precision diagnostics. The new module is now available to over 700 women's health providers at more than 300 practice sites across 20 states, impacting the care of over 1.5 million patients annually. This initiative aligns with Aspira's strategy to expand the adoption of its Ova1Plus® and OvaWatch® products efficiently. Aspira CEO Mike Buhle expressed pride in this milestone, highlighting its significance in enhancing value for providers, patients, and the company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspira Women's Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040229) on June 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2544283969?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-17 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544283969","market":"us","top_or_hot":-1,"title":"Aspira Women's Health Inc. Partners with Dorsata to Launch Adnexal Mass Clinical Tool, Expanding Access to 1.5 Million Patients Across 300+ Practices","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AWH\">Aspira Women's Health Inc.</a> Partners with Dorsata to Launch Adnexal Mass Clinical Tool, Expanding Access to 1.5 Million Patients Across 300+ Practices\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AWHL\">Aspira Women's Health Inc.</a> has announced a new collaboration with Dorsata to launch a clinical decision support module for adnexal masses. This partnership aims to modernize women's healthcare by integrating tech-enabled clinical tools to facilitate early detection and precision diagnostics. The new module is now available to over 700 women's health providers at more than 300 practice sites across 20 states, impacting the care of over 1.5 million patients annually. This initiative aligns with Aspira's strategy to expand the adoption of its Ova1Plus® and OvaWatch® products efficiently. Aspira CEO Mike Buhle expressed pride in this milestone, highlighting its significance in enhancing value for providers, patients, and the company.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspira Women's Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040229) on June 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aspira Women's Health Inc. Partners with Dorsata to Launch Adnexal Mass Clinical Tool, Expanding Access to 1.5 Million Patients Across 300+ Practices</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAspira Women's Health Inc. Partners with Dorsata to Launch Adnexal Mass Clinical Tool, Expanding Access to 1.5 Million Patients Across 300+ Practices\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-17 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AWH\">Aspira Women's Health Inc.</a> Partners with Dorsata to Launch Adnexal Mass Clinical Tool, Expanding Access to 1.5 Million Patients Across 300+ Practices\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AWHL\">Aspira Women's Health Inc.</a> has announced a new collaboration with Dorsata to launch a clinical decision support module for adnexal masses. This partnership aims to modernize women's healthcare by integrating tech-enabled clinical tools to facilitate early detection and precision diagnostics. The new module is now available to over 700 women's health providers at more than 300 practice sites across 20 states, impacting the care of over 1.5 million patients annually. This initiative aligns with Aspira's strategy to expand the adoption of its Ova1Plus® and OvaWatch® products efficiently. Aspira CEO Mike Buhle expressed pride in this milestone, highlighting its significance in enhancing value for providers, patients, and the company.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspira Women's Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040229) on June 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AWH","symbol_name":"Aspira Women's Health Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL1Gtxv0:1","article_id":"2544283969","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544283969","pubTimestamp":1750158054,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aspira Women's Health Inc. Partners with Dorsata to Launch Adnexal Mass Clinical Tool, Expanding Access to 1.5 Million Patients Across 300+ Practices. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspira Women's Health Inc. published the original content used to generate this news brief via ACCESS Newswire  on June 17, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AWH":"Aspira Women's Health Inc.","BK4082":"医疗保健设备","AWHL":"Aspira Women's Health Inc."},"translate_title":"Aspira Women's Health Inc.与Dorsata合作推出Adnexal Mass临床工具，将覆盖范围扩大到300多家诊所的150万患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AWH":0.9,"AWHL":0.9},"content_text":"Aspira Women's Health Inc. Partners with Dorsata to Launch Adnexal Mass Clinical Tool, Expanding Access to 1.5 Million Patients Across 300+ Practices\n    \n\nAspira Women's Health Inc. has announced a new collaboration with Dorsata to launch a clinical decision support module for adnexal masses. This partnership aims to modernize women's healthcare by integrating tech-enabled clinical tools to facilitate early detection and precision diagnostics. The new module is now available to over 700 women's health providers at more than 300 practice sites across 20 states, impacting the care of over 1.5 million patients annually. This initiative aligns with Aspira's strategy to expand the adoption of its Ova1Plus® and OvaWatch® products efficiently. Aspira CEO Mike Buhle expressed pride in this milestone, highlighting its significance in enhancing value for providers, patients, and the company.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspira Women's Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1040229) on June 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2544283969","isCrawlerRequest":true}